Acute megakaryoblastic leukemia pathophysiology

Revision as of 03:35, 19 April 2021 by Israrkhan (talk | contribs)
Jump to navigation Jump to search

Acute megakaryoblastic leukemia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute megakaryoblastic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute megakaryoblastic leukemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute megakaryoblastic leukemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute megakaryoblastic leukemia pathophysiology

CDC on Acute megakaryoblastic leukemia pathophysiology

Acute megakaryoblastic leukemia pathophysiology in the news

Blogs on Acute megakaryoblastic leukemia pathophysiology

Directions to Hospitals Treating Acute megakaryoblastic leukemia

Risk calculators and risk factors for Acute megakaryoblastic leukemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology


  • It is associated with GATA1, and risks are increased in individuals with Down syndrome.[1] However, not all cases are associated with Down syndrome,[2] and other genes can also be associated with AMKL.[3]
  • Myelofibrosis is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the fibroblasts obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.[5]
  • Transforming Growth Factor-β (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on collagen.[6]



References

  1. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A (2003). "GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome". Blood. 101 (11): 4301–4. doi:10.1182/blood-2003-01-0013. PMID 12586620.
  2. Hama A, Yagasaki H, Takahashi Y; et al. (2008). "Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome". Br. J. Haematol. 140 (5): 552–61. doi:10.1111/j.1365-2141.2007.06971.x. PMID 18275433.
  3. Gu TL, Mercher T, Tyner JW; et al. (2007). "A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia". Blood. 110 (1): 323–33. doi:10.1182/blood-2006-10-052282. PMID 17360941.
  4. Bennett, John M. (1985). "Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)". Annals of Internal Medicine. 103 (3): 460. doi:10.7326/0003-4819-103-3-460. ISSN 0003-4819.
  5. Clare, Nanette; Elson, David; Manhoff, Louis (1982). "Cytogenetic Studies of Peripheral Myeloblasts and Bone Marrow Fibroblasts in Acute Myelofibrosis". American Journal of Clinical Pathology. 77 (6): 762–766. doi:10.1093/ajcp/77.6.762. ISSN 0002-9173.
  6. Terui, T; Niitsu, Y; Mahara, K; Fujisaki, Y; Urushizaki, Y; Mogi, Y; Kohgo, Y; Watanabe, N; Ogura, M; Saito, H (1990). "The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis". Blood. 75 (7): 1540–1548. doi:10.1182/blood.V75.7.1540.1540. ISSN 0006-4971.

Template:WH Template:WS